Biodexa Pharmaceuticals Plc: Form 6-K Summary (Interim Results to June 30, 2023)
Business Context and Reporting Period
This Form 6-K reports the unaudited interim results for Biodexa Pharmaceuticals Plc (NASDAQ: BDRX) for the six months ended June 30, 2023. Biodexa is a clinical-stage biopharmaceutical company focused on developing therapies for primary and metastatic brain cancers. The reporting period covers significant strategic realignment, including the de-listing from AIM, a name change, and a pivot from a drug delivery platform to a therapeutics company centered on its lead candidate, MTX110.
Key Financial Metrics
| Metric | 1H 2023 | 1H 2022 |
|---|---|---|
| Total Revenue | £0.30m | £0.47m |
| Net Loss | £3.57m | £3.06m |
| Research & Development Costs | £2.25m | £2.41m |
| Administrative Expenses | £2.29m | £1.85m |
| Net Cash Used in Operating Activities | £3.88m | £3.54m |
| Net Cash Generated from Financing | £6.25m | (£0.08m) |
| Cash Balance (June 30, 2023) | £5.23m | £6.42m (June 30, 2022) |
| Accumulated Deficit | £138.97m | N/A |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by 36% to £0.30m, driven by lower income from the R&D collaboration with Janssen Pharmaceutica NV.
- Cost Structure: R&D costs decreased by 7% due to staff reductions (seven redundancies), partially offset by increased Phase I clinical trial costs for MTX110. Administrative expenses rose 24% primarily due to legal and professional fees associated with financings and an aborted acquisition.
- Financing Activity: The company raised approximately $9.3m gross proceeds in two US transactions: a $6.0m private placement in February and a $3.3m registered direct offering in May. This resulted in a net cash inflow of £2.39m for the period, reversing the outflow seen in 1H22.
- Share Capital: Significant dilution occurred through the issuance of ADSs and warrants. A share consolidation (1-for-20) and subsequent subdivision/redesignation were approved by shareholders.
Outlook, Risks, and Management Commentary
Strategic Realignment: Management has repositioned the company as a therapeutics developer focused on MTX110 (a liquid formulation of panobinostat delivered via convection-enhanced delivery) for recurrent glioblastoma and diffuse midline glioma. The drug delivery platform (Q-Sphera) has been de-prioritized.
Clinical Progress: The Data Safety Monitoring Board approved dose escalation of MTX110 to 90µM in recurrent glioblastoma. Enrolment of nine patients in the Phase I study for diffuse midline glioma was completed post-period end. A new preclinical program, MTD217, combining MTX110 with an oxidative phosphorylation inhibitor, has been initiated.
Going Concern and Liquidity Risk: The filing contains a material uncertainty regarding the company's ability to continue as a going concern. Directors forecast cash resources will fund operations only into the first quarter of 2024. Failure to secure additional financing before that date could result in administration. The financing environment for small-cap biotechs is described as challenging, and future capital raises are likely to be dilutive.
Contingencies: The company has a contingent liability of $225,000 related to the reimbursement of expenses for the aborted acquisition of Bioasis Technologies, Inc., which was voted down by shareholders in January 2023.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the forecast that cash reserves (£5.23m) will sustain operations only until Q1 2024.
- Dilution Impact: Assess the extent of shareholder dilution from the February and May 2023 financings, including the exercise of pre-funded and cashless warrants.
- MTX110 Clinical Data: Monitor upcoming data readouts from the recurrent glioblastoma and diffuse midline glioma Phase I trials to validate the "therapeutics" pivot strategy.
- Financing Options: Evaluate the likelihood of securing further capital in the current market environment to avoid administration.
- Bioasis Contingency: Confirm the status of the $225,000 contingent liability regarding the failed Bioasis acquisition.